Sutro Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STRO research report →
Range $43 – $60
Price Chart
About the company
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders.
- CEO
- Jane Chung
- IPO
- 2018
- Employees
- 128
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on STRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $139.84M
- P/E
- -0.83
- PEG
- -0.03
- P/S
- 3.06
- P/B
- -2.32
- EV/EBITDA
- -0.72
- Div Yield
- 0.00%
- Gross Margin
- 97.20%
- Op Margin
- -309.87%
- Net Margin
- -395.25%
- ROE
- 185.30%
- ROIC
- -95.49%
Latest fiscal year · YoY change
- Revenue
- $102.48M+65.2%
- Gross Profit
- $95.16M+73.6%
- Op Income
- $-104,952,000
- Net Income
- $-191,086,000+16.0%
- EPS
- $-22.49+24.0%
- OCF Growth
- +7.5%
- FCF Growth
- +8.1%
- 52W High
- $43.85
- 52W Low
- $7.15
- 50D MA
- $20.03
- 200D MA
- $23.00
- Beta
- 1.50
- RSI (14)
- 24
- Avg Volume
- 296.30K
No earnings-call transcripts are available for STRO yet.
- Free Float
- 70.6%
- Shares Outstanding
- 9.68M
- Float Shares
- 6.83M
of shares held by institutions
72 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Perceptive Advisors LLC | 1.30M | ▲ 589.54K |
| Bvf Inc/Il | 1.25M | 0 |
| Affinity Asset Advisors, LLC | 1.17M | ▲ 102.97K |
| Blackrock, Inc. | 1.12M | ▲ 889.97K |
| Samsara Biocapital, LLC | 1.06M | 0 |
| Kynam Capital Management, LP | 872.56K | 0 |
| Orbimed Advisors LLC | 743.94K | ▼ 57.20K |
| Balyasny Asset Management L.P. | 711.16K | ▲ 245.37K |
| Vanguard Capital Management LLC | 694.22K | ▼ 26.22K |
| Eventide Asset Management, LLC | 585.26K | ▼ 130.04K |
| Velan Capital Investment Management LP | 512.16K | 0 |
| Woodline Partners LP | 458.03K | ▲ 588 |
Held by 143 ETFs
Biggest fund positions in STRO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | Gerber Hans-Peter | other | 3,750 |
| Sep 18, 26 | Gerber Hans-Peter | other | 1,345 |
| Sep 18, 26 | Gerber Hans-Peter | other | 3,750 |
| Jun 5, 26 | Wigginton Jon Marc | other | 10,000 |
| Jun 5, 26 | Petree Daniel H | other | 10,000 |
| Jun 5, 26 | PANEK JAMES P | other | 10,000 |
| Jun 5, 26 | Lobacki Joseph M | other | 10,000 |
| Jun 5, 26 | Jagpal Sukhi | other | 10,000 |
| Jun 5, 26 | Hunter Heidi | other | 10,000 |
| Jun 5, 26 | Dybbs Michael | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STRO coverage
Recent articles, reports, and earnings notes.
No research on STRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STRO report →Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
globenewswire.com · Sep 29
Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head Analysis
defenseworld.net · Aug 29
Why is Sutro Biopharma Stock Falling On Wednesday?
benzinga.com · Aug 12
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
globenewswire.com · Aug 12
Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More
247wallst.com · Aug 7
Affinity Asset Advisors LLC Grows Stock Holdings in Sutro Biopharma, Inc. $STRO
defenseworld.net · Jul 25
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
globenewswire.com · May 14
Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More
247wallst.com · Apr 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.